[go: up one dir, main page]

WO2000026185A3 - Omeprazole solution and method of using same - Google Patents

Omeprazole solution and method of using same Download PDF

Info

Publication number
WO2000026185A3
WO2000026185A3 PCT/US1999/025592 US9925592W WO0026185A3 WO 2000026185 A3 WO2000026185 A3 WO 2000026185A3 US 9925592 W US9925592 W US 9925592W WO 0026185 A3 WO0026185 A3 WO 0026185A3
Authority
WO
WIPO (PCT)
Prior art keywords
metal
group
proton pump
pump inhibitor
bicarbonate salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/025592
Other languages
French (fr)
Other versions
WO2000026185A9 (en
WO2000026185A2 (en
Inventor
Jeffrey O Phillips
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Missouri Columbia
University of Missouri St Louis
Original Assignee
University of Missouri Columbia
University of Missouri St Louis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Missouri Columbia, University of Missouri St Louis filed Critical University of Missouri Columbia
Priority to AU19071/00A priority Critical patent/AU1907100A/en
Publication of WO2000026185A2 publication Critical patent/WO2000026185A2/en
Publication of WO2000026185A3 publication Critical patent/WO2000026185A3/en
Publication of WO2000026185A9 publication Critical patent/WO2000026185A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method of treating gastric acid disorders by administering to a patient a pharmaceutical composition including a proton pump inhibitor in a pharmaceutically acceptable carrier including a bicarbonate salt of a Group IA metal where the administering step consists of a single dosage form without requiring further administering of the bicarbonate salt of the Group IA metal. A pharmaceutical composition includes a dry formulation of a proton pump inhibitor in a pharmaceutically acceptable carrier including a bicarbonate salt of a Group IA metal. A pharmaceutical composition for making a dry formulation of a proton pump inhibitor which includes a proton pump inhibitor and a bicarbonate salt of a Group IA metal in a form for convenient storage, whereby when the composition is in a dry formulation which is suitable for enteral administration.
PCT/US1999/025592 1998-10-30 1999-10-29 Omeprazole solution and method of using same Ceased WO2000026185A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU19071/00A AU1907100A (en) 1998-10-30 1999-10-29 Omeprazole solution and method of using same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18342298A 1998-10-30 1998-10-30
US09/183,422 1998-10-30

Publications (3)

Publication Number Publication Date
WO2000026185A2 WO2000026185A2 (en) 2000-05-11
WO2000026185A3 true WO2000026185A3 (en) 2000-08-10
WO2000026185A9 WO2000026185A9 (en) 2000-09-21

Family

ID=22672726

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/025592 Ceased WO2000026185A2 (en) 1998-10-30 1999-10-29 Omeprazole solution and method of using same

Country Status (2)

Country Link
AU (1) AU1907100A (en)
WO (1) WO2000026185A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6780882B2 (en) 1996-01-04 2004-08-24 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
USRE45198E1 (en) 1996-01-04 2014-10-14 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
MY137726A (en) 2000-11-22 2009-03-31 Nycomed Gmbh Freeze-dried pantoprazole preparation and pantoprazole injection
AU2003273000A1 (en) 2002-10-16 2004-05-04 Takeda Pharmaceutical Company Limited Stable solid preparations
CA2531566C (en) * 2003-07-18 2013-05-07 Santarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
WO2025078989A1 (en) 2023-10-11 2025-04-17 Reena Patel Stabilized pharmaceutical compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853230A (en) * 1986-04-30 1989-08-01 Aktiebolaget Hassle Pharmaceutical formulations of acid labile substances for oral use
US5753265A (en) * 1994-07-08 1998-05-19 Astra Aktiebolag Multiple unit pharmaceutical preparation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853230A (en) * 1986-04-30 1989-08-01 Aktiebolaget Hassle Pharmaceutical formulations of acid labile substances for oral use
US5753265A (en) * 1994-07-08 1998-05-19 Astra Aktiebolag Multiple unit pharmaceutical preparation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NAKAGAWA ET AL.: "Phase I study of Lansoprazole (AG-1749), anticulcer agent", JOURNAL OF CLINICAL THERAPEUTICS & MEDICINES,, vol. 7, no. 1, January 1991 (1991-01-01), pages 33 - 50, XP002928123 *
PILBRANT ET AL.: "Development of an oral formulation of omeprazole", SCAND J. GASTROENTEROL.,, vol. 20, (SUPPL. 108), 1985, pages 113 - 120, XP002928124 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6780882B2 (en) 1996-01-04 2004-08-24 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
USRE45198E1 (en) 1996-01-04 2014-10-14 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them

Also Published As

Publication number Publication date
AU1907100A (en) 2000-05-22
WO2000026185A9 (en) 2000-09-21
WO2000026185A2 (en) 2000-05-11

Similar Documents

Publication Publication Date Title
US4778810A (en) Nasal delivery of caffeine
IS1694B (en) Medicinal product for administration to oral animals containing proton pump blockers
IE871981L (en) Programmed release formulation.
TW359614B (en) Composition containing benzimidazole compounds for rectal administration
WO2002019999A3 (en) Compositions for treating sexual dysfunction, containing an no-donor and an antioxidant
CA2336945A1 (en) Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
WO2002019969A3 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
NZ514129A (en) Tolperison-containing, pharmaceutical preparation for oral administration
WO2001041742A3 (en) Antiviral medication
UA66812C2 (en) Drug formulation with controlled release of active ingredient
WO2000026185A3 (en) Omeprazole solution and method of using same
CA2383212A1 (en) Controlled release oral dosage suitable for oral administration
NO950134L (en) Formulations for orally administered pharmaceutical agents
IE894050L (en) Compound with gastric acid inhibitory effect and process for¹its preparation
AU4898890A (en) A system for the controlled release of active agents and a process for its preparation
WO1991018606A3 (en) Orally active nonaddicting analgesics
WO2000048582A3 (en) Pharmaceutical composition containing desoxypeganine for the treatment of drug dependence
EP0271151A3 (en) Azumolene dosage form
ATE212550T1 (en) MEDICINAL PREPARATIONS CONTAINING TIAGABINE WITH CONTROLLED ADMINISTRATION OF ACTIVE INGREDIENTS
AU2907800A (en) Pharmaceutical composition containing desoxypeganine for the treatment of alcoholism
WO2002053097A3 (en) Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
WO2002069968A8 (en) New use
WO2001045727A3 (en) Stabilized veterinary compositions comprising more than one antiviral agent
AU2001258859A1 (en) Pralmorelin-containing nasal drop preparations
RU99112967A (en) METHOD FOR TREATMENT AND PREVENTION OF PIG DYSENTERY

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 45, 47 AND 48, DESCRIPTION, REPLACED BY NEW PAGES 45, 47 AND 48; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase